C. Theillet, J Adelaide, G Louason, J Adnane, J S Hernandez-Gonzalez, J Jacquemier, P Gaudray, D Birnbaum
Abstracts of papers presented at the Cold Spring Harbor Meeting of Cancer Cells
Genetics and molecular biology of breast cancer symposium,Cold Spring Harbor, NY (United States),2-6 Sep 1992
( Page 73 )
Pinchar Aquí:
https://www.osti.gov/servlets/purl/10190599
Abstracts of papers presented at the Cold Spring Harbor Meeting of Cancer Cells
Genetics and molecular biology of breast cancer symposium,Cold Spring Harbor, NY (United States),2-6 Sep 1992
FLG/FGFRI AND PLAT AS MARKERS OF AMPLIFICATION AT CHROMOSOME 8P12 IN BREAST AND OVARIAN CANCERS
Abstracts of papers presented at the Cold Spring Harbor Meeting of Cancer Cells
Genetics and molecular biology of breast cancer symposium,Cold Spring Harbor, NY (United States),2-6 Sep 1992
FLG/FGFRI and PLAT as markers of amplification at chromosome 8p12 in breast and ovarian cancers.
C. Theillet, J Adelaide, G Louason, J Adnane, J S Hernandez-Gonzalez, J Jacquemier, P Gaudray, D Birnbaum
Two FGF receptor (FGFR) genes, FLG/FGFRI
and BEK/FGFR2 located at 8p12 and I0q26 respectively, are amplified in approximately
12% of primary breast tumors (Adnane et al., Oncogene, 1991). We focused our efforts on the 8p12 region and extended our analysis to another marker of this region, PLAT.
In our series of 173 breast cancers,
FLG/FGFRI and PLAT were respectively amplified in 14.5% and 15.6% on the cases and both events
were frequently concommitant, but also occurred independently. In I01 ovarian cancers,
amplification of PLAT (12.7 _o) was observed more frequently than that of FLGF/FGFRI (4.9%). The amplification of PLAT in tumors where FLG/FGFRI showed a normal copy number casted some doubt on the identity of the gene selected in the amplicon. Therefore, we undertook an analysis of the RNA expression of both FLG/FGFRI and PLAT in a panel of 68 breast tumors showing normal copy number or amplification at the concerned loci. The expression pattern of PLAT excluded this gene since its levels of expression were, in most tumors, indistinguishable from those observed in normal mammary tissue. Contrastingly, FLG/FGFRI showed variable levels of expression, with overexpression in amplified and non amplified samples. We also noticed amplified tumors which did not overexpress this gene. These results suggest that neither FLG/FGFRI nor PLAT behave as targets of the amplification observed at chromosome 8p12.
Fuente: https://www.osti.gov/servlets/purl/10190599
